Ciliated stent-like-system

Information

  • Patent Grant
  • 8092549
  • Patent Number
    8,092,549
  • Date Filed
    Friday, September 24, 2004
    20 years ago
  • Date Issued
    Tuesday, January 10, 2012
    12 years ago
Abstract
A ciliated stent-like system and method of operating the same.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is related to, claims the earliest available effective filing date(s) from (e.g., claims earliest available priority dates for other than provisional patent applications; claims benefits under 35 USC §119(e) for provisional patent applications), and incorporates by reference in its entirety all subject matter of the following listed applications; the present application also claims the earliest available effective filing date(s) from, and also incorporates by reference in its entirety all subject matter of any and all parent, grandparent, great-grandparent, etc. applications of the following listed applications:

  • 1. United States patent application entitled A SYSTEM FOR PERFUSION MANAGEMENT, naming Lowell L. Wood Jr. as inventor, filed 19 Apr. 2004 and assigned U.S. application Ser. No. 10/827,576.
  • 2. United States patent application entitled A SYSTEM WITH A SENSOR FOR PERFUSION MANAGEMENT, naming Lowell L. Wood Jr. as inventor, filed 19 Apr. 2004 and assigned U.S. application Ser. No. 10/827,578.
  • 3. United States patent application entitled A SYSTEM WITH A RESERVOIR FOR PERFUSION MANAGEMENT, naming Lowell L. Wood Jr. as inventor, filed 19 Apr. 2004 and assigned U.S. application Ser. No. 10/827,572.
  • 4. United States patent application entitled A TELESCOPING PERFUSION MANAGEMENT SYSTEM, naming Lowell L. Wood Jr. as inventor, filed 19 Apr. 2004 and assigned U.S. application Ser. No. 10/827,390.


TECHNICAL FIELD

The present application relates, in general, to endoprosthetic devices for the treatment and/or management of disease, disorders, or conditions.


SUMMARY

In one aspect, a device includes but is not limited to: a flexible hollow portion with an outer surface and an inner surface and wherein the flexible hollow portion is sized for placement in a location in a receiver; and a plurality of movable parts coupled to the inner surface of the flexible hollow portion, the movable parts operable as a group for moving particles. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present application.


In one aspect, a method includes but is not limited to: forming a supporting passage implantable in an animal; coupling a plurality of moving parts to the supporting passage; and sizing the supporting passage and the plurality of moving parts coupled to the supporting passage for placement in a location in the animal. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present application.


In one aspect, a method includes but is not limited to: placing a hollow expandable device in a luminal portion of a recipient wherein the interior of the hollow expandable device is coupled to a plurality of moving pieces; positioning the hollow expandable device in the lumen of the organ; and monitoring the hollow expandable device. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present application.


In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.


In one or more various aspects, related systems include but are not limited to energy- and power-management circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.


In addition to the foregoing, various other method and or system aspects are set forth and described in the text (e.g., claims and/or detailed description) and/or drawings of the present application.


The foregoing is a summary and thus contains, by necessity; simplifications, generalizations and omissions of detail; consequently, those skilled in the art will appreciate that the summary is illustrative only and is NOT intended to be in any way limiting. Other aspects, inventive features, and advantages of the devices and/or processes described herein, as defined solely by the claims, will become apparent in the non-limiting detailed description set forth herein.





BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 is a plan view of an embodiment of ciliated stent-like system 100.



FIG. 2 is a plan view of various aspects of the ciliated stent-like system 100.



FIG. 3 is one aspect of a cross sectional view of the ciliated stent-like system 100.



FIG. 4 is one aspect of a cross sectional view of the ciliated stent-like system 100.



FIG. 5 is a diagrammatic view of one aspect of the ciliary movement in the interior of the ciliated stent-like system 100.



FIG. 6 is a diagrammatic view of one aspect of the ciliary movement in the interior of the ciliated stent-like system 100.



FIG. 7 is an illustration of the ciliated stent-like system 100 implanted in a trachea or a bronchial tree portion 701.





The use of the same symbols in different drawings typically indicates similar or identical items.


DETAILED DESCRIPTION

The present application uses formal outline headings for clarity of presentation. However, it is to be understood that the outline headings are for presentation purposes, and that different types of subject matter may be discussed throughout the application (e.g., device(s)/structure(s) may be described under the process(es)/operations heading(s) and/or process(es)/operations may be discussed under structure(s)/process(es) headings). Hence, the use of the formal outline headings is not intended to be in any way limiting.


1. A Ciliated Stent-Like System(s) and/or Process(es).


With reference now to FIG. 1, shown is a side plan view illustrative of various exemplary ciliated stent-like system(s) and/or process(es). Accordingly, the present application first describes certain specific exemplary structures of FIG. 1; thereafter, the present application illustrates certain specific exemplary processes. Those having skill in the art will appreciate that the specific devices, systems and processes described herein are intended as merely illustrative of their more general counterparts.


It will also be appreciated by those skilled in the art that in one embodiment, the ciliated stent-like system includes a powered ciliated stent-like system. Furthermore, while the structure is referred to as a ciliated stent-like system, the terminology is not intended to be limiting. The term stent-like system may for example, refer stents or similar devices that may include any structure or device for providing support to an orifice, such as, for example, slender rods, threads, or catheters.


A. Structure(s) and or Device(s)


With reference to the figures, and with reference now to FIG. 1, shown is a plan view of a ciliated stent-like system 100. The ciliated stent-like system 100 is an endoprosthetic device which may be employed in a recipient, a receiver, or a host, for example, an animal. In one aspect, the ciliated stent-like system 100 may be inserted into a lumen of a vessel threading a tissue or organ or portion thereof. The surface of the ciliated stent-like system 100 may include surface modifications to attach to or to positionally contact the vessel walls of the animal. For example, the surface modifications may include bumps 101, rings, grooves, ridges, or contours, one or more of which may be power-actuated. In one aspect, the ciliated stent-like system 100 is a longitudinal or elongated device with a substantially hollow interior. The ciliated stent-like system 100 may be used as an intraluminal prosthetic device to repair, open, evacuate, replace, medicate or support a lumen in the recipient. For example, the lumen of a vessel threading a tissue or an organ may be a part of a vascular system, a neurovascular system, a urogenital tract, a pulmonary tract, a gastrointestinal tract, or any other lumen-threaded tissue or organ or portion thereof.


With reference to the figures, and with reference now to FIG. 2, depicted is a plan view of various aspects of the ciliated stent-like system 100. In one aspect, the ciliated stent-like system 100 may have an open configuration. In another aspect, the ciliated stent-like system 100 may have a flexible, compressible, or expansive configuration. The ciliated stent-like system 100 may be self-expanding, balloon expandable, dilatable or contractible under control of an embedded controller. Expansion may be achieved, for example, by including an expandable material or a specific configuration, or a combination. For example, the expandable material, includes but is not limited to, nickel-cobalt-chromium based alloys, or titanium. Furthermore, expandability can also be configured by using a coil or spring-like configuration, or via any of many types of powered devices or mechanisms.


Continuing to refer to FIG. 2, in another aspect, the ciliated stent-like system 100 may have an open flexible configuration. Such a configuration would permit the ciliated stent-like system 100 to be minimized in size for insertion. On insertion at a location the ciliated stent-like system 100 may expand to provide support. The shape or type of the ciliated stent-like system 100 may depend on the location of its use. For example, the ciliated stent-like system 100 may have a helical coil shape (FIGS. 2A and 2B), a tubular mesh shape (FIG. 2C), a bifurcated shape (FIG. 2D), an irregular Y shape, or an elongated segmented shape including taper (FIG. 2E). In one aspect, the ciliated stent-like system 100 may be formed from a single wire, or have an open lattice or network structure. Additional information can be found, for example, in U.S. Pat. Nos. 5,395,390 and 5,234,457 both of which are hereby incorporated by reference in their entirety. In one aspect, the ciliated stent-like system 100 may include a segmented structure, for example, for promoting flexibility and closer adherence to the lumen. In another aspect, the ciliated stent-like system 100 may include one or more expandable forks or branches, for example, for enhancing the support and/or removal of occluded material. Additionally, the ciliated stent-like system 100 may include attachments, including but not limited to, an evacuating device, a siphon, a sensor, an actuator, a device for storing materials, a device for releasing materials stored, a controller, or a device for providing telemetry solutions.


Some or all of the parts, for example, the tissue-contacting parts, of the ciliated stent-like system 100 may be formed from a biocompatible material, a shape memory material or a metal such as, for example, nickel titanium alloy, metal, silicon, plastic or polymer. Examples of polymers include but are not limited to, polyethylene, polypropylene, polyglycolic acid, polylactic acid, cellulose acetate, or cellulose nitrate. In one aspect some or all of the parts of the ciliated stent-like system 100 may be made of a biodegradable material. In another aspect, the ciliated stent-like system 100 may be coated by one or more polymers or materials which are, for example, biocompatible, organic or biodegradable.


Furthermore, the ciliated stent-like system 100 may be used to deliver an agent, for example, including but not limited to, by passive delivery or under control of an controller either internal or external to the ciliated stent-like system 100. In one aspect, when delivering the agent by passive delivery, the ciliated stent-like system 100 may be coated with one or more agents, such as, for example, including, but not limited to, a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, or a peptide.


In one aspect the ciliated stent-like system 100 is sized for placement in the recipient, for example, including but not limited to, in a lumen of a blood vessel in an adult human body. In another aspect the ciliated stent-like system 100 is sized for placement, for example, in the lumen of an organ in a pediatric body. In one example, the size of the diameter of the stent may be about 1-2 cm. In another example, both of the exterior and the interior diameters of the ciliated stent-like system 100 may be uniform or may vary to accommodate dimensions of the location of insertion, placement of functionality-conferring devices, or functionality of the ciliated stent-like system 100. In another example, the ciliated stent-like system 100 may be sized to fit within a portion of a bronchial tree, wherein the internal diameter of portions of the bronchial tree is about 0.1-10 mm. It is also within the scope of the invention, that the ciliated stent-like system 100 may be used to replace, fully or partially, the functionality of the section portion of the bronchial tree. In this example, the outer diameter of the ciliated stent-like system 100 has a diameter corresponding to about the external diameter of the portion of the bronchial tree.


With reference now to FIG. 3, and with reference now to FIG. 4, depicted is one aspect of a cross sectional view of the ciliated stent-like system 100. In one aspect, the ciliated stent-like system 100 may have an outer surface 312 made of a metal and coated with a polymer. The outer surface 312 may have a coefficient of friction lower or higher in comparison to an inner surface 311 promoting the adherence of the outer surface 312 of the ciliated stent-like system 100, for example, to the bounding walls of the lumen. The outer surface 312 may also include surface protuberances 101, for example, to position or adhere the ciliated stent-like system 100, for example, to the bounding walls of the lumen. The inner surface 311 may have a low coefficient of friction to promote flow of air, fluid, debris, fluidized particles, exudates, particles, mucus, or debris. The inner surface 311 may be smooth to decrease the attachment or adherence of materials, thereby decreasing occlusion. The overall coefficient of friction of the outer surface 312 need only be of a sufficient value to permit the device to be reasonably secured to and/or positioned within a region and to minimize unwanted migration. Thus, the value of the coefficient of friction, for the ciliated stent-like system 100, will vary and, in one example, depend on the location of its use, or its intended use. It is known in the art that the coefficient of friction of Teflon-coated surfaces, for example, is about 0.05, the coefficient of friction of skin is about 0.8, and that of steel is about 0.58. In one exemplary aspect, the coefficient of friction of the inner surface 311 is between 0.0001 to about 0.58, whereas the coefficient of friction for the outer surface 312 is at least about 0.0001. In other applications or other aspects, the coefficient of friction of the inner surface 311 and the coefficient of friction for the outer surface 312 may differ from these ranges, and the ranges should not be considered limiting.


In one aspect, the ciliated stent-like system 100 has a plurality of cilia 320 and 321 arranged in the inner surface 311 of the ciliated stent-like system 100. The plurality of cilia may include one or more movable parts attached to the ciliated stent-like system 100. In one aspect, the plurality of cilia 320 and 321 may be arranged, for example, in rows, columns, or similarly-ordered groupings. The plurality of cilia 320 and 321 may fully or partially encompass the inner surface 311. In one aspect, the length, the dimensions or other configuration aspects of the cilia will depend on the intended functions of the cilia. For example, where a pulmonary ciliated stent is employed in a trachea or a bronchi, the ciliary movement may help degrade occlusions or the formation thereof. In this example, the cilia may be long, the undulatory movement of the cilia may be responsible for moving, expelling or propelling, for example, fluid, clots, occlusive material, or fluid, particles, fluidized particles, mucus, exudate or biological debris. In another aspect, the plurality of cilia 320 and 321, may be a combination of various ciliary lengths suitable for operating an undulating propelling mechanism. It will be appreciated by those skilled in the art that the plurality of cilia 320 and 321 includes, but is not limited to, cilia-like functional structures and/or cilia-like appearing structures.


In one aspect the plurality of cilia 320 and 321 may be arranged on the inner surface 311 of the ciliated stent-like system 100. However, it is within the scope of the invention to include the plurality of cilia 320 and 321 on the outer surface 312 or on both surfaces. It is also within the scope of the invention, that the plurality of cilia 320 and 321 present on the outer surface 312 or the inner surface 311 may differ, for example, in the type of cilia, control mechanism associated with the cilia, and/or the function performed by the plurality of cilia 320 and 321. For example, the plurality of cilia 320 and 321 present on the outer surface 311 may be of a type, or have features that aid in the placement of the ciliated stent-like system 100 in a location in a recipient whereas the plurality of cilia 320 and 321 present on the inner surface 312 may be of a type or have features that perform other functions.


With reference now to FIG. 5, in one aspect, the plurality of cilia 320 and 321 may include an actuator made of a self-oscillating polymer gel. Additional information may be found in an article by O. Tabata, H. Hirasawa, K, and S. Aoki “Ciliary Motion Actuator using Self-Oscillating gel.” The 14th Annual International Conference On Micro ElectroMechinical Systems, pp. 405-408, 2001, which is herein incorporated by reference. In another aspect, both the plurality of cilia 320 and 321 may be made of self-oscillating polymer gel. The self-oscillating polymer gel exhibits spontaneous swelling 520 and deswelling 521 and is responsible for propagating a wave motion. Ciliary movement, includes but is not limited to, up and down, undulating, wave like, pulsing, vectorial, oscillating, circular, lateral, vertical, rhythmic, or sideways movement or the like. Ciliary movement need not be limited to larger movements, but may include nanoscale-level movements.


Ciliary movement may be self-propagating or induced. For example, with regards to a pulmonary ciliated stent, induction may occur when a particle touches a cilium, or when the patient coughs, or otherwise moves or actuates his/her chest. Actuation may make use of stored energy, derived, for example, from previous motion; in the pulmonary case, for example, this motion may be that associated with inhalation and/or exhalation or with myocardial motion. The ciliated stent-like system 100 may be part of a disposable stent, for example, where the majority of the stent is composed of biodegradable or other material subject to solubilization or disintegration within the body. It will be appreciated by those skilled in the art that techniques for fabricating such cilia from self-oscillating polymer gels are well known in and are herein incorporated by reference. It will also be appreciated by those skilled in the art that techniques for favoring ciliary-driven transport in one direction along the stent relative to the other, particularly when a power source is available, are well-known and are herein incorporated by reference.


In another aspect, the plurality of cilia 310 and 321 includes one or more flexible polymeric rods. Additional information may be found in a presentation by R. L. Carroll, B. Wilde, R. M. Taylor, L. Vicci, S. Washburn, and R. Superfine, “Biomimetic Flexible Polymer Rods—Artificial Cilia.” The 70th Annual meeting of the Southeastern Section of the American Physical Society, Nov. 6-8, 2003. Polymeric rods imitating ciliary structures are known structures. The polymeric rods may have a length about 10 microns, and a diameter of about 800 nm and would be able to propel fluid, fluidized particles, mucus, exudate or biological debris. However, polymeric rods of different dimensions are within the scope of the invention. In one example, the one or more flexible polymeric rods includes magnetic material. External oscillating magnetic fields may manipulate or actuate the flexible polymeric fields, for example, directly or by inductive coupling to an energy-store and/or power supply within the stent. It will be appreciated by those skilled in the art that such techniques and similar techniques are known, and are herein incorporated by reference.


In another aspect, the plurality of cilia 320 and 321 includes one or more MEMS micro-actuator arrays. It will be appreciated by those skilled in the art that the one or more MEMS micro-actuator arrays may be made to perform various modes of oscillatory movement and could be included in the interior of the ciliated stent-like system 100, for example, to provide a force for moving fluid, particles, fluidized particles, mucus, exudate or biological debris through the interior of the ciliated stent-like system 100. It will be appreciated by those skilled in the art that MEMS fabrication and actuation techniques are known in the art, and are herein incorporated by reference.


With reference now to the FIG. 6, in one aspect, the plurality of cilia 320 and 321 are arranged, for example, in a centralized group or an array 620. Each cilium may have, for example, a modified paddle-shaped structure for efficiently moving fluid, fluidized particles, particles, mucus, exudate or biological debris.


In one aspect, the plurality of cilia 310 and 321 or the array 620 includes one or more actuator arrays, for example, MEMS actuator arrays. The MEMS actuator arrays may be coated with a thin film of a material that improves the physical, chemical, or electronic, properties of the array, for example, including, but not limited to, polyimide. The MEMS actuator arrays may promote the sensorless manipulation of small objects using thermal and electrostatic control mechanisms. In one aspect the MEMS actuator arrays may be arranged, for example, including but not limited to, on the inner surface 311 of the ciliated stent-like system 100. The actuator arrays may be capable of providing a wide variety of movements, such as, for example, translation, rotation, centering, or orientation. Additionally, they may induce a low-level gait to the plurality of cilia 320 and 321, such as, for example, up-and-down motion, cyclical motion, or flagelatory motion resulting in the fluid, particles, fluidized particles, mucus, exudate or biological debris, being moved. In this example, the speed of the moving fluid, particles, fluidized particles, mucus, exudate or biological debris is dependant on the displacement of the actuators per cycle, the number of times the cycle is repeated per unit of time, the surface properties of the particle to be moved, the weight of the particle to be moved, the local surface tension, the local orientation relative to the direction of gravity or other acceleration field, etc. In another example, the one or more MEMS actuator arrays may be used to induce a high-level control, or a high-level gait, such as, for example, orienting and aligning fluid, particles, fluidized particles, mucus, exudate or biological debris. In this example, the one or more MEMS actuator arrays may be used to position or rotate an obstructing or blocking particle for its expulsion or removal from the lumen of a vessel. It will be appreciated by those skilled in the art that such techniques are known in the art and are herein incorporated by reference. Additional information may be found in an article by W. Suh, R. B. Darling, K. F. Böhringer, B. R. Donald, H. Baltes, G. T. A. Kovacs, “Fully Programmable MEMS Ciliary Actuator Arrays for Micromanipulation Tasks.” IEEE International Conference on Robotics and Automation (ICRA), pp. 1101-1108, San Francisco, Calif., April 2000, which is herein incorporated by reference.


Continuing to refer to FIG. 6, in one example, the plurality of cilia 320 and 321, for example, may move in a programmed or otherwise controlled rhythm. The plurality of cilia 320 and 321 may extend to an upward extended position 621 from a middle resting position, to a downward position 623 before returning to the middle resting position. In another example the resting position of the plurality of cilia 320 and 321 may be the downward position 623. Other combinations of synchronous or non-synchronous beatings of the plurality of cilia 320 and 321 are within the scope of the invention, including those in which one or more waves of ciliary action are made to propagate along some selected direction relative to the local axis of the stent.


In another aspect, motors may be included in the plurality of cilia 320 and 321 to provide the energy or to generate the force needed for moving fluid, particles, fluidized particles, mucus, exudate or biological debris or fluid. In one example, protein molecule-based motors, such as those employing kinesin or dynein, may be used to provide motive force for ciliary rotational or directional movement. For example, including but not limited to, the direction of the movement of the biological molecular motors, is influenced by the orientation of any tubulin present, or the matrix that the motors may use as their tracks. In one aspect, ATP hydrolysis may provide the energy for the actuation of the biological molecular motors, and ATP and ATPase may be furnished, for example, by coupling mitochondria to the biological molecular motors. In another example, the actin-myosin system may be included in the plurality of cilia 320 and 321 in order to provide the force for moving fluid, particles, fluidized particles, mucus, exudate or biological debris. It will be appreciated by those skilled in the art that such techniques are known in the art and are herein incorporated by reference. This subject is described in further detail by N. Thomas and R. A. Thornhill in the Journal of Physics D: Applied Physics 31, pages 253-266, 7 Feb. 1998, and by Carlo Montemagno, George Bachand, Scott Stelick, and Marlene Bachand in Nanotechnology 10:225-231, 1999, both of which are herein incorporated by reference.


In another aspect, the plurality of cilia 320 and 321 includes an electro-active transducer with an electroactive polymer, which deflects in response to an electrical field. In one example, the deflection of the electroactive polymer is operable to move fluid. In another example, the deflection of the electroactive polymer is operable to move fluid, particles, fluidized particles, mucus, exudate or biological debris, such as, for example, congealed or clotted liquids. The transducer includes at least two electrodes in electrical communication with the electroactive polymer. Deflection of the electroactive polymer may produce a range of motions, including, but not limited to, one or more of a rotational, vibrational, linear, flagelatory or the like. Additional information regarding electroactive polymers can be found in U.S. Patent Application No. 2004/0008853 which is herein incorporated by reference.


In another aspect, the plurality of cilia 320 and 321 includes, for example, electrostrictive materials, such as, piezoelectric materials, or magnetostrictive materials. These materials may be actuated by application of electric or magnetic fields, respectively, sourced, for example, by a power source internal or external to the ciliated stent-like system 100. In one aspect, the power source may be external to the ciliated stent-like system 100 but internal to the recipient. For example, including, but not limited to, acoustic energy may be sourced from either within the ciliated stent-like system 100, from elsewhere within the recipient in which the ciliated stent-like system 100 is located. In another aspect, the power source may be external to the recipient, for example, power may be supplied to the ciliated stent-like system 100 from outside of the recipient, including powering actuation of the plurality of cilia 320 and 321, either directly or indirectly. In yet another aspect, the power source may be internal to the ciliated stent-like system 100.


In another aspect, control of ciliary motion may be performed by a controller, for example, including, but not limited to, one centered on a digital microprocessor, embedded in whole or in part within the ciliated stent-like system 100 or the powered stent-like system. Such embedded controller may be interrogated or programmed with acoustic-, wired- or optical-circuitry or via wireless transmission of electrically-, magnetically- or electromagnetically-conveyed signals. Such controller may be informed by one or more sensors within the ciliated stent-like system 100 or the powered stent-like system. Such controller may, from time-to-time in a programmed manner, also direct release of one or more materials from one or more reservoirs or storage compartments located within the ciliated stent-like system 100 or the powered stent-like system, or may direct, monitor or control one or more large-scale motions of part or all of the ciliated stent-like system 100 or the powered stent-like system system 100.


Provision of energy to the power the ciliated stent-like system 100 includes, but is not limited to, including one or more primary or secondary batteries possibly embedded into, battery-recharging or direct power transfer via body-external magnetic, electric, acoustic, gross-mechanical-motion or optical fields applied for this purpose, a system generating chemical energy possibly embedded within the system. In one aspect, energy may be recharged or regenerated. For example, by external or intra-body sources, and transduction/conversion of kinetic energy deriving from action of one or more muscles of the body in which the ciliated stent-like system 100 or the powered stent-like system is embedded or implanted, for example, including but not limited to, inertial-mechanical-electrical transduction.


The ciliated stent-like system 100 or the powered stent-like system may include additional devices, integrated devices, or properties for diametrically expanding and/or contracting, as well as translating along the axis of the local lumen, any portion of the system, including all of it. These may include, but aren't limited to, mechanical devices, such as, for example, linear motors, electro- or magneto-strictive actuators, tractive devices, pneumatic actuators, peristaltic devices, etc.


The ciliated stent-like system 100 or the powered stent-like may include additional devices, integrated devices, or properties for sensing and/or quantitatively measuring to a specified accuracy one or more features or variables of its environment, for processing, storing and transmitting such information to a body-external receiver, and for receiving control or interrogation information from one or more body-external points.


The format of materials which may be stored and/or released by the ciliated stent-like system 100 includes, but is not limited to, liquids, gases, emulsions, gels, mists, sprays, dusts, powders, aerosolized or carbureted particulate matter of all types, and the composition thereof may be one or more of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, or a peptide, a contrast agent, or a pharmacological agent.


B. Operation(s) and/or Process(es)


With reference to the figures, and with reference now to FIG. 7, is an illustration of the ciliated stent-like system 100 implanted in a trachea 701. In another implementation the ciliated stent-like system 100 is implanted in a bronchiole 703, or a bronchi 702 or any part of the bronchial tree. In other implementations, the ciliated stent-like system 100 is not restricted to the pulmonary system but is employed in the lumen of any vessel or organ of the recipient, for example, any vessel in an animal body.


In one implementation, the ciliated stent-like system 100 includes, but is not limited to, an external controller for manipulating the ciliated stent-like system 100 and/or the plurality of cilia 320 and 321. Manipulation of the ciliated stent-like system 100 may include, for example, expelling, moving, guiding, positioning or repositioning the ciliated stent-like system 100. In one example, the ciliated stent-like system 100 may be controlled or manipulated from a remote location by medical personnel. In another example, the ciliated stent-like system 100 may be controlled or manipulated external to the recipient. In another implementation, the external controller may include a monitoring system, and/or wireless circuitry for manipulating the ciliated stent-like system 1000 and/or the plurality of cilia 320 and 321.


In one implementation, the ciliated stent-like system 100 includes a system or apparatus for removing or relocating biological debris of various types, such as, for example, fluid, particles, fluidized particles, mucus, exudate or biological debris. For example, the apparatus or the system may include a siphon connected to a monitor for visualizing the debris field. Observable debris may then be siphoned by positioning and operating the siphon. In one example, the siphon may be used in collaboration with the plurality of cilia 320 and 321. In this example, the plurality of cilia 320 and 321 may be used to gather and/or expel any debris and the siphon employed to collect and/or relocate the gathered or expelled debris, for example, from within one or more locations in the pulmonary tract into the esophagus.


In one implementation, the use of the ciliated stent-like system 100 includes, but is not limited to, the treatment of pulmonary diseases, such as, for example, chronic obstructive pulmonary disease (COPD). COPD includes diseases characterized by dyspnea or disorders characterized by, such as, for example, chronic bronchitis, asthma, or emphysema. Additional information may be found in the following two articles by P. J. Barnes, “Small Airways in COPD.” New England Journal of Medicine, 350:256, pages 2635-2637, Jul. 04, 2004, and by E. R. Sutherland, R. M. Cherniack, “Management of Chronic Obstructive Pulmonary Disease”, pages 2689-2697, Jun. 24, 2004, which is herein incorporated by reference. In another implantation, the ciliated stent-like system 100 may be configured to address diseases, such as, for example, cystic fibrosis, in which under-performance of the muco-ciliary system results in the accumulation of mucus, exudates and pathogens in the lung, causing prolonged, occasionally life-threatening infections. In this example, the ciliated stent-like system 100 may be employed to help clear the air passages by expelling actively, for example, fluid, fluidized particles, mucus, exudate or biological debris, including in conjunction with release and/or dispersal of surfactants or viscosity-modulating agents, either from the ciliated stent-like system 100 or from other sources.


In one implementation, the plurality of cilia 320 and 321 are programmed for moving intermittently. In another implementation, the plurality of cilia 320 and 321 may be programmed to move continuously. It will be appreciated by those skilled in the art that the movements of the plurality of cilia 320 and 321 may be adjusted depending on a number of criteria, for example, the area of use or the specifics of the task required to be performed.


C. Variation(s), and/or Implementation(s)


Those having skill in the art will recognize that the present application teaches modifications of the devices, structures, and/or processes within the spirit of the teaching herein. For example, the ciliated stent-like system 100 need not be limited to a cylindrical or tubular shape. For example, the ciliated stent-like system 100 may have a composite or multi-segmented flexible shape to provide a best fit in the use-location in the animal. In another example, the ciliated stent-like system 100 may have a substantially planar or conical shape, or may change its shape markedly as it installs within or transverses a luminal tract of a vessel within an animal. Other modifications of the subject matter herein will be appreciated by one of skill in the art in light of the teachings herein.


It will also be appreciated by those skilled in the art that the ciliated stent-like system 100 may be made of materials that render it fully or partially disposable. In one example, the outer surface 312 of the ciliated stent-like system 100 is designed to deliver an agent or perform functions to remove an obstruction, and then disintegrate. For example, the outer surface 312 of the ciliated stent-like system 100 may be coated with the agent which is made to contact the walls of the lumen. The main body of the ciliated stent-like system 100 may be designed to disintegrate or dissolve over a certain interval of time leaving the agent on/within the lumen. Alternatively, the ciliated stent-like system 100 may release one or more agents into the lumen itself, either continually or under program control. Any such agent may be replenished by reloading into a compartment or reservoir within the ciliated stent-like system 100. Other modifications of the subject matter herein will be appreciated by one of skill in the art in light of the teachings herein.


It will also be appreciated by those skilled in the art that the ciliated stent-like system 100 may include wireless or robotic attachments for controlling it from the exterior of the recipient or animal in which it is placed. Other modifications of the subject matter herein will be appreciated by one of skill in the art in light of the teachings herein.


The foregoing described aspects depict different components contained within, or connected with, different other components. It is to be understood that such depicted architectures are merely exemplary, and that in fact many other architectures can be implemented which achieve the same functionality. In a conceptual sense, any arrangement of components to achieve the same functionality is effectively “associated” such that the desired functionality is achieved. Hence, any two components herein combined to achieve a particular functionality can be seen as “associated with” each other such that the desired functionality is achieved, irrespective of architectures or intermedial components. Likewise, any two components so associated can also be viewed as being “operably connected”, or “operably coupled”, to each other to achieve the desired functionality.


While particular aspects of the present subject matter described herein have been shown and described, it will be obvious to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from this subject matter described herein and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of this subject matter described herein. Furthermore, it is to be understood that the invention is defined solely by the appended claims. It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to inventions containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations), etc.

Claims
  • 1. A device, comprising: a flexible hollow portion with an outer surface and an inner surface;a plurality of movable parts coupled to the inner surface of the flexible hollow portion; andthe plurality of movable parts configured to contact a material and including a control mechanism configured to induce controllable motion of the plurality of movable parts to generate a force for moving the material within the hollow portion.
  • 2. The device of claim 1, wherein the flexible hollow portion comprises: a substantially tubular or cylindrical structure.
  • 3. The device of claim 2, wherein the a substantially tubular or cylindrical structure comprises: at least one of a substantially expandable, or contractile structure.
  • 4. The device of claim 2, wherein the substantially tubular or cylindrical structure flexible comprises: an expandable mesh.
  • 5. The device of claim 2, wherein the substantially tubular or cylindrical structure comprises: a plurality of expandable segments coupled to the plurality of movable parts.
  • 6. The device of claim 2, wherein the substantially tubular or cylindrical structure comprises: one or more of a metal, silicon, polymer, plastic, organic, or biodegradable material.
  • 7. The device of claim 2, wherein the substantially tubular or cylindrical structure further comprises: a coating of one or more of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, polymer, or a biodegradable material.
  • 8. The device of claim 1, wherein the flexible hollow portion comprises: a shape or configuration for placement in the location.
  • 9. The device of claim 1, wherein the flexible hollow portion comprises: one or more forks or branches.
  • 10. The device of claim 1, wherein the flexible hollow portion comprises: a substantially smooth inner surface.
  • 11. The device of claim 1, wherein the flexible hollow portion comprises: an inner surface with a low coefficient of friction operable for low-impedance flow of air or fluid.
  • 12. The device of claim 1, wherein the flexible hollow portion comprises: an outer surface with a surface modification operable for adhesion, adherence or positioning to the location in the host.
  • 13. The device of claim 12, wherein the surface modification comprises: one or more of a groove, bump, ridge, ring or contour.
  • 14. The device of claim 1, wherein the host includes: an animal or a plant.
  • 15. The device of claim 1, wherein the plurality of movable parts comprises: one or more of a gel, a hydrogel, a colloid, a polymer, an oscillating polymer, an electro-active polymer, a polymer, an electro- or magneto-strictive material, a linear motor-device, or a material coated with a biologically compatible material.
  • 16. The device of claim 1, wherein the plurality of movable parts comprises: a low-level gait or motion for moving fluid, particles, fluidized particles, mucus, exudate or debris.
  • 17. The device of claim 1, wherein the plurality of movable parts comprises: a high-level gait or motion for moving fluid, particles, fluidized particles, mucus, exudate, or debris.
  • 18. The device of claim 1, wherein the control mechanism comprises: an actuator, a motor, a biomolecular motor, or a device operable for providing motion coupled to the plurality of movable parts.
  • 19. The device of claim 1, wherein the control mechanism comprises: a MEMS device.
  • 20. The device of claim 1, wherein the control mechanism comprises: a magnetic material.
  • 21. The device of claim 1, wherein the control mechanism comprises: an electroactive polymer.
  • 22. The device of claim 1, wherein the control mechanism comprises: an electrorestrictive material.
  • 23. The device of claim 1, wherein the device further comprises: a mechanism for dispensing of at least one of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, a polymer, or a biodegradable material.
  • 24. A device, comprising: a flexible hollow portion with an outer surface and an inner surface;a plurality of movable parts coupled to the inner surface of the flexible hollow portion, the plurality of movable parts configured to contact a material and configured to generate a movable force on the material; anda controller configured to provide an electric, magnetic, acoustic, optical or electromagnetic field to the plurality of movable parts for controlling the plurality of movable parts or the flexible hollow portion.
  • 25. A system, comprising: a device including a flexible hollow portion with an outer surface and an inner surface and wherein the flexible hollow portion is sized for placement in a location in a host;a plurality of movable parts coupled to the inner surface of the flexible hollow portion, the plurality of movable parts operable as a group and configured for contacting and moving particles; andan external or internal a controller configured to provide an electric, magnetic, acoustic, optical or electromagnetic field for controlling the device.
  • 26. A device, comprising: a flexible hollow portion with an outer surface and an inner surface;a plurality of movable parts coupled to the inner surface of the flexible hollow portion, the plurality of movable parts configured to contact a material and including a control mechanism configured to induce controllable motion of the plurality of movable parts to generate a force for moving the material within the hollow portion; anda reservoir for storing one or more of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, a polymer, or a biodegradable material.
  • 27. The device of claim 26, wherein the flexible hollow portion further comprises: one or more movable parts coupled to the outer surface of the flexible hollow portion.
  • 28. The device of claim 26, wherein the device further comprises: a mechanism for powering the device.
  • 29. The device of claim 28, wherein the mechanism for powering the device further comprises: a mechanism for obtaining or storing energy.
  • 30. A method of making a device, comprising: forming a supporting passage implantable in a host;coupling a plurality of moving parts to the supporting passage, wherein the plurality of moving parts are configured to contact a material and include a control mechanism configured to induce controllable motion of the plurality of movable parts to generate a force for moving the material within the hollow portion; andsizing the supporting passage and the plurality of moving parts coupled to the supporting passage for placement in a location in the host.
  • 31. The method of claim 30, wherein the method further comprises: forming the supporting passage wherein at least a portion of the supporting passage is at least one of substantially flexible, compressible, or expansile.
  • 32. The method of claim 30, wherein the method further comprises: forming the supporting passage including a substantially expandable tubular or cylindrical part coupled to the plurality of moving parts.
  • 33. The method of claim 30, wherein the method further comprises: forming the supporting passage including an expandable mesh coupled to the plurality of moving parts.
  • 34. The method of claim 30, wherein the method further comprises: forming the supporting passage coupled to the plurality of moving parts configured for placement in the location in the host.
  • 35. The method of claim 30, wherein the method further comprises: forming a bifurcated supporting passage.
  • 36. The method of claim 30, wherein the method further comprises: forming the supporting passage or plurality of moving parts with one or more of a metal, silicon, polymer, plastic, inorganic, organic, or biodegradable material.
  • 37. The method of claim 30, wherein the method further comprises: coating at least a portion of the supporting passage or plurality of moving parts with a biocompatible material, polymer, biodegradable material, drug, medicinal agent, or therapeutic agent.
  • 38. The method of claim 30, wherein the method further comprises: producing a smooth surface in at least a portion of the interior of the supporting passage.
  • 39. The method of claim 30, wherein the method further comprises: making surface modifications in the exterior of the supporting passage operable for attaching to or positioning about the location in the host.
  • 40. The method of claim 39, wherein the method further comprises: forming surface modifications including grooves, contours, ridges, rings or bumps in the exterior of the supporting passage.
  • 41. The method of claim 30, wherein the method further comprises: forming the supporting passage or the plurality of moving parts including one or more of a gel, a hydrogel, a colloid, a polymer, an oscillating polymer, an electro-active polymer, a polymer, or a material coated with a biologically-compatible material.
  • 42. The method of claim 30, wherein the method further comprises: orienting the plurality of moving parts radially outward.
  • 43. The method of claim 30, wherein the method further comprises: configuring the plurality of moving parts to define a low-level gait or motion.
  • 44. The method of claim 30, wherein the method further comprises: configuring the plurality of moving parts to define a high-level gait or motion.
  • 45. The method of claim 30, wherein the method further comprises: operably-coupling an actuator, a motor, a biomolecular motor, or a device operable for providing motion to the plurality of moving parts.
  • 46. The method of claim 30, wherein the method comprises: forming the supporting passage with a custom size, shape, configuration, or dimension for placing in a trachea, a bronchi, a bronchial tree, a urogenital tract, a gastrointestinal tract, a pulmonary tract, a neurovascular system, or a vascular system.
  • 47. The method of claim 30, wherein the method comprises: forming the supporting passage with a custom size, shape, configuration, or dimension for replacing or functionally supplanting at least a portion of a trachea, a bronchi, a bronchial tree, a urogenital tract, a gastrointestinal tract, a pulmonary tract, a neurovascular system, or a vascular system.
  • 48. The method of claim 30, wherein the method further comprises: coupling an external control system to the plurality of moving parts or the supporting passage.
  • 49. The method of claim 30, wherein the method further comprises: including an external control system for remotely operating or manipulating the device.
  • 50. The method of claim 30, wherein the method further comprises: coupling a monitor to the supporting passage.
  • 51. The method of claim 30, wherein the method further comprises: coupling a debris-removing, debris-displacing or debris-relocating system to the supporting passage.
  • 52. The method of claim 30, wherein the method further comprises: providing a storage system for storing at least one of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, a polymer, or a biodegradable material.
  • 53. The method of claim 30, wherein the method further comprises: coating at least a portion of the device with at least one of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, a polymer, or a biodegradable material.
  • 54. The method of claim 30, wherein the method further comprises: including a mechanism for releasing one or more of a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, a polymer, or a biodegradable material.
  • 55. The method of claim 30, wherein the method further comprises: storing energy internal or external to the device.
  • 56. The method of claim 30, wherein the method further comprises: providing a mechanism for obtaining power.
  • 57. The method of claim 30, wherein the method further comprises: coupling the plurality of moving parts to at least one of an interior wall or an exterior wall of the supporting passage.
  • 58. A method of making a device, comprising: forming a supporting passage implantable in a host;coupling a plurality of moving parts to the supporting passage, the the plurality of movable parts configured to contact a material and including a control mechanism configured to induce controllable motion of the plurality of movable parts to generate a force for moving the material within the hollow portion;sizing the supporting passage and the plurality of moving parts coupled to the supporting passage for placement in a location in the host; andincluding an actuator operable for controlling the motion or direction of the one or more moving parts.
  • 59. A method, comprising: placing a hollow expandable device in a luminal portion of a recipient wherein the hollow expandable device includes an outer surface and an inner surface, wherein a plurality of moving parts are coupled to the inner surface, wherein the plurality of movable parts including a control mechanism configured to induce controllable motion of the plurality of movable parts to generate a force for moving material within the hollow portion;positioning the hollow expandable device in the lumen of an organ; andmonitoring the hollow expandable device.
  • 60. The method of claim 59, wherein the method further comprises: adjusting, guiding, positioning, directing, or activating the hollow expandable device.
  • 61. The method of claim 59, wherein the method further comprises: removing the hollow expandable device.
  • 62. The method of claim 59, wherein the method further comprises: activating the one or more moving parts coupled to the hollow expandable device to move fluid, particles, fluidized particles, mucus, exudate or debris.
  • 63. The method of claim 59, wherein the method further comprises: placing the hollow expandable device in a trachea, a bronchi, a bronchial tree, a urogenital tract, a gastrointestinal tract, a pulmonary tract, a neurovascular system, or a vascular system.
  • 64. The method of claim 59, wherein the method further comprises: controlling a motion or directionality of the one or more of moving parts.
  • 65. The method of claim 59, wherein the method further comprises: adjusting the orientation of the one or more of moving parts.
  • 66. The method of claim 59, wherein the method further comprises: placing the hollow expandable device wherein the hollow expandable device has at least one fork.
  • 67. The method of claim 66, wherein the method further comprises: positioning the at least one fork.
  • 68. The method of claim 59, wherein the method further comprises: removing any debris.
  • 69. The method of claim 59, wherein the method further comprises: monitoring the hollow expandable device remotely.
  • 70. The method of claim 59, wherein the method further comprises: positioning the hollow expandable device and the one or more of moving parts remotely.
  • 71. The method of claim 59, wherein the method further comprises: charging the hollow expandable device.
  • 72. The method of claim 59, wherein the method further comprises: delivering a drug, a medicinal agent, a therapeutic agent, a biologically active agent, a chemical, a chemical compound, a surfactant, a steroid, a luminal-dilating agent, a luminal-contracting agent, an antibiotic or antifungal or antiviral agent, a protein, a nucleic acid or a polymer comprised of one or more nucleic acids, a macromolecule, a peptide, polymer, or a biodegradable material.
  • 73. A method, comprising: placing a hollow expandable device in a luminal portion of a host wherein the interior of the hollow expandable device is coupled to one or more moving parts, the one or more moving parts configured for contacting and moving particles;positioning the hollow expandable device in the lumen of an organ;monitoring the hollow expandable device; andapplying at least one of an external electric, magnetic, acoustic, optical or electromagnetic field for removing fluid, particles, fluidized particles, mucus, exudate or debris.
  • 74. A method, comprising: placing a hollow flexible device in a luminal portion of a host, the hollow flexible device having an interior configured to permit entry and exit of a material;wherein the interior of the hollow flexible device includes one or more moving parts, the one or more moving parts configured to contact the material and to controllably move the material;positioning the hollow flexible device in the lumen of an organ; andapplying at least one of an external electric, magnetic, acoustic, optical or electromagnetic field to the one or more movable parts.
US Referenced Citations (401)
Number Name Date Kind
3391697 Greatbatch Jul 1968 A
3821469 Whetstone et al. Jun 1974 A
3837339 Aisenberg et al. Sep 1974 A
3941127 Froning Mar 1976 A
3983474 Kuipers Sep 1976 A
4054881 Raab Oct 1977 A
4119900 Kremnitz Oct 1978 A
4202349 Jones May 1980 A
4262306 Renner Apr 1981 A
4314251 Raab Feb 1982 A
4317078 Weed et al. Feb 1982 A
4339953 Iwasaki Jul 1982 A
4367741 Michaels Jan 1983 A
4396885 Constant Aug 1983 A
4403321 Krüger Sep 1983 A
4418422 Richter et al. Nov 1983 A
4431005 McCormick Feb 1984 A
4583190 Salb Apr 1986 A
4585652 Miller et al. Apr 1986 A
4628928 Lowell Dec 1986 A
4638798 Shelden et al. Jan 1987 A
4642786 Hansen Feb 1987 A
4651732 Frederick Mar 1987 A
4658214 Petersen Apr 1987 A
4714460 Calderon Dec 1987 A
4717381 Papantonakos Jan 1988 A
4733661 Palestrant Mar 1988 A
4763667 Manzo Aug 1988 A
4769006 Papantonakos Sep 1988 A
4771772 DeWitt Sep 1988 A
4800898 Hess et al. Jan 1989 A
4805615 Carol Feb 1989 A
4817601 Roth et al. Apr 1989 A
4871351 Feingold Oct 1989 A
4889526 Rauscher et al. Dec 1989 A
4905689 Stack et al. Mar 1990 A
4943296 Funakubo et al. Jul 1990 A
4944659 Labbe et al. Jul 1990 A
4962453 Pong et al. Oct 1990 A
4994071 MacGregor Feb 1991 A
5019372 Folkman et al. May 1991 A
5031109 Gloton Jul 1991 A
5051906 Evans, Jr. et al. Sep 1991 A
5078140 Kwoh Jan 1992 A
5086401 Glassman et al. Feb 1992 A
5153827 Coutre et al. Oct 1992 A
5165064 Mattaboni Nov 1992 A
5176638 Michael Jan 1993 A
5188111 Yates et al. Feb 1993 A
5204814 Noonan et al. Apr 1993 A
5234457 Andersen Aug 1993 A
5269303 Wernicke et al. Dec 1993 A
5279607 Schentag et al. Jan 1994 A
5310404 Gyory et al. May 1994 A
5313835 Dunn May 1994 A
5314451 Mulier May 1994 A
5321614 Ashworth Jun 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5337732 Grundfest et al. Aug 1994 A
5338625 Bates et al. Aug 1994 A
5339051 Koehler et al. Aug 1994 A
5353807 DeMarco Oct 1994 A
5374285 Vaiani et al. Dec 1994 A
5381786 Spears Jan 1995 A
5386741 Rennex Feb 1995 A
5395390 Simon et al. Mar 1995 A
5398670 Ortiz et al. Mar 1995 A
5403311 Abele et al. Apr 1995 A
5411551 Winston et al. May 1995 A
5437660 Johnson et al. Aug 1995 A
5476450 Ruggio Dec 1995 A
5497147 Arms et al. Mar 1996 A
5502638 Takenaka Mar 1996 A
5507287 Palcic et al. Apr 1996 A
5522394 Zurbrugg Jun 1996 A
5551953 Lattin et al. Sep 1996 A
5554914 Miyazawa Sep 1996 A
5569968 Lal et al. Oct 1996 A
5574347 Neubauer Nov 1996 A
5589932 Garcia-Rubio et al. Dec 1996 A
5593434 Williams Jan 1997 A
5599324 McAlister et al. Feb 1997 A
5610488 Miyazawa Mar 1997 A
5624398 Smith et al. Apr 1997 A
5632754 Farley et al. May 1997 A
5643296 Hundertmark et al. Jul 1997 A
5662587 Grundfest et al. Sep 1997 A
5669874 Feiring Sep 1997 A
5670329 Oberhardt Sep 1997 A
5674276 Andersen et al. Oct 1997 A
5688269 Newton et al. Nov 1997 A
5695457 St. Goar et al. Dec 1997 A
5697967 Dinh et al. Dec 1997 A
5702432 Chen et al. Dec 1997 A
5705293 Hobson Jan 1998 A
5728089 Lal et al. Mar 1998 A
5737279 Carter Apr 1998 A
5758298 Guldner May 1998 A
5782798 Rise Jul 1998 A
5804563 Still et al. Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5819736 Avny et al. Oct 1998 A
5827190 Palcic et al. Oct 1998 A
5830179 Mikus et al. Nov 1998 A
5830207 Leeb et al. Nov 1998 A
5831012 Nilsson et al. Nov 1998 A
5833603 Kovacs et al. Nov 1998 A
5843139 Goedeke et al. Dec 1998 A
5855801 Lin et al. Jan 1999 A
5873835 Hastings et al. Feb 1999 A
5908027 Butterfield et al. Jun 1999 A
5921982 Lesh et al. Jul 1999 A
5947119 Reznick Sep 1999 A
5954675 Dellagatta Sep 1999 A
5964773 Greenstein Oct 1999 A
6004269 Crowley et al. Dec 1999 A
6016449 Fischell et al. Jan 2000 A
6019729 Itoigawa et al. Feb 2000 A
6022316 Eppstein et al. Feb 2000 A
6053873 Govari et al. Apr 2000 A
6086528 Adair Jul 2000 A
6108597 Kirchner et al. Aug 2000 A
6111520 Allen et al. Aug 2000 A
6128538 Fischell et al. Oct 2000 A
6134474 Fischell et al. Oct 2000 A
6149603 Parker Nov 2000 A
6159230 Samuels Dec 2000 A
6164284 Schulman et al. Dec 2000 A
6170488 Spillman, Jr. et al. Jan 2001 B1
6175757 Watkins et al. Jan 2001 B1
6179789 Tu et al. Jan 2001 B1
6185452 Schulman et al. Feb 2001 B1
6186986 Berg et al. Feb 2001 B1
6187599 Asher et al. Feb 2001 B1
6197013 Reed et al. Mar 2001 B1
6219577 Brown, III et al. Apr 2001 B1
6221099 Andersen et al. Apr 2001 B1
6240312 Alfano et al. May 2001 B1
6240316 Richmond et al. May 2001 B1
6248345 Goldenheim et al. Jun 2001 B1
6249076 Madden et al. Jun 2001 B1
6255361 Rajagopalan et al. Jul 2001 B1
6255793 Peless et al. Jul 2001 B1
6263245 Snell Jul 2001 B1
6278379 Allen et al. Aug 2001 B1
6289270 Baumgarten Sep 2001 B1
6295990 Lewis et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6322532 D'Sa et al. Nov 2001 B1
6337997 Rise Jan 2002 B1
6372248 Qin et al. Apr 2002 B1
6383162 Sugarbaker May 2002 B1
6384741 O'Leary, Sr. May 2002 B1
6385472 Hall et al. May 2002 B1
6398280 Parker et al. Jun 2002 B1
6402678 Fischell et al. Jun 2002 B1
6409674 Brockway et al. Jun 2002 B1
6417641 Peless et al. Jul 2002 B2
6436120 Meglin Aug 2002 B1
6442413 Silver Aug 2002 B1
6450937 Mercereau et al. Sep 2002 B1
6453199 Kobozev Sep 2002 B1
6464687 Ishikawa et al. Oct 2002 B1
6475639 Shahinpoor et al. Nov 2002 B2
6490483 Willis Dec 2002 B2
6493607 Bourne et al. Dec 2002 B1
6497714 Ishikawa et al. Dec 2002 B1
6500174 Maguire et al. Dec 2002 B1
6512949 Combs et al. Jan 2003 B1
6512950 Li et al. Jan 2003 B2
6514237 Maseda Feb 2003 B1
6530950 Alvarado et al. Mar 2003 B1
6547723 Ouchi Apr 2003 B1
6547825 Shimizu et al. Apr 2003 B1
6548982 Papanikolopoulos et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6575969 Rittman, III et al. Jun 2003 B1
6585763 Keilman et al. Jul 2003 B1
6591137 Fischell et al. Jul 2003 B1
6592567 Levin et al. Jul 2003 B1
6597954 Pless et al. Jul 2003 B1
6607553 Healy et al. Aug 2003 B1
6612982 Ouchi Sep 2003 B1
6616676 Bashiri et al. Sep 2003 B2
6623519 Edwin et al. Sep 2003 B2
6632216 Houzego et al. Oct 2003 B2
6638273 Farley et al. Oct 2003 B1
6648908 Dobak, III et al. Nov 2003 B2
6666860 Takahashi Dec 2003 B1
6669683 Santini, Jr. et al. Dec 2003 B2
6673042 Samson et al. Jan 2004 B1
6673363 Luo et al. Jan 2004 B2
6679893 Tran Jan 2004 B1
6709388 Mosse et al. Mar 2004 B1
6711423 Colvin, Jr. Mar 2004 B2
6712835 Mazzocchi et al. Mar 2004 B2
6719684 Kim et al. Apr 2004 B2
6735474 Loeb et al. May 2004 B1
6735475 Whitehurst et al. May 2004 B1
6743211 Prausnitz et al. Jun 2004 B1
6754536 Swoyer et al. Jun 2004 B2
6755802 Bell Jun 2004 B2
6755803 Le et al. Jun 2004 B1
6764441 Chiel et al. Jul 2004 B2
6773429 Sheppard, Jr. et al. Aug 2004 B2
6776165 Jin Aug 2004 B2
6797522 Still et al. Sep 2004 B1
6802811 Slepian Oct 2004 B1
6816632 Slice Nov 2004 B1
6824508 Kim et al. Nov 2004 B2
6824510 Kim et al. Nov 2004 B2
6824561 Soykan et al. Nov 2004 B2
6834118 Kim Dec 2004 B2
6849183 Gorsuch et al. Feb 2005 B2
6855115 Fonseca et al. Feb 2005 B2
6860867 Seward et al. Mar 2005 B2
6861001 Lee et al. Mar 2005 B2
6866626 Long et al. Mar 2005 B2
6875209 Zvuloni et al. Apr 2005 B2
6889091 Hine et al. May 2005 B2
6890303 Fitz May 2005 B2
6898464 Edell et al. May 2005 B2
6911004 Kim et al. Jun 2005 B2
6911496 Rhee et al. Jun 2005 B2
6920359 Meadows et al. Jul 2005 B2
6921413 Mahadevan-Jansen et al. Jul 2005 B2
6925357 Wang et al. Aug 2005 B2
6929636 Von Alten Aug 2005 B1
6936003 Iddan Aug 2005 B2
6939290 Iddan Sep 2005 B2
6939376 Shulze et al. Sep 2005 B2
6950707 Whitehurst Sep 2005 B2
6953589 Trautman et al. Oct 2005 B1
6958034 Iddan Oct 2005 B2
6959215 Gliner et al. Oct 2005 B2
6960227 Jones et al. Nov 2005 B2
6963792 Green Nov 2005 B1
6984205 Gazdzinski Jan 2006 B2
6984952 Peless et al. Jan 2006 B2
6991617 Hektner et al. Jan 2006 B2
7003352 Whitehurst Feb 2006 B1
7013177 Whitehurst et al. Mar 2006 B1
7020231 Frey et al. Mar 2006 B1
7027134 Garcia-Rubio et al. Apr 2006 B1
7037343 Imran May 2006 B2
7039453 Mullick et al. May 2006 B2
7042184 Oleynikov et al. May 2006 B2
RE39133 Clayton et al. Jun 2006 E
7083578 Lewkowicz et al. Aug 2006 B2
7101386 Dobak, III Sep 2006 B2
7115109 Gerdts et al. Oct 2006 B2
7118531 Krill Oct 2006 B2
7125382 Zhou et al. Oct 2006 B2
7131979 DiCarlo et al. Nov 2006 B2
7160258 Imran et al. Jan 2007 B2
7171285 Kim et al. Jan 2007 B2
7181261 Silver et al. Feb 2007 B2
7212110 Martin et al. May 2007 B1
7214182 Shimizu et al. May 2007 B2
7228162 Ward et al. Jun 2007 B2
7236821 Cates et al. Jun 2007 B2
7245954 Glukhovsky Jul 2007 B2
7297113 Russell et al. Nov 2007 B1
7341577 Gill Mar 2008 B2
7365509 Park et al. Apr 2008 B2
7365614 McCorquodale et al. Apr 2008 B2
7383071 Russell et al. Jun 2008 B1
7398734 Jean Jul 2008 B1
7451537 Liu et al. Nov 2008 B2
7486967 Pan et al. Feb 2009 B2
7572228 Wolinsky et al. Aug 2009 B2
7596403 Horn Sep 2009 B2
7625338 Gilad et al. Dec 2009 B2
7684840 Palti Mar 2010 B2
7713196 Baker, Jr. May 2010 B2
7736300 Ziegler et al. Jun 2010 B2
7744542 Piaget et al. Jun 2010 B2
7801626 Moser Sep 2010 B2
7840271 Kieval et al. Nov 2010 B2
7857767 Ferren et al. Dec 2010 B2
20010029348 Willis Oct 2001 A1
20010051766 Gazdzinski Dec 2001 A1
20020065509 Lebel et al. May 2002 A1
20020068080 Lerner Jun 2002 A1
20020090388 Humes et al. Jul 2002 A1
20020103417 Gazdzinski Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020147480 Mamayek Oct 2002 A1
20020156462 Stultz Oct 2002 A1
20020165592 Glukhovsky et al. Nov 2002 A1
20020169436 Gurm et al. Nov 2002 A1
20020171385 Kim et al. Nov 2002 A1
20020188323 Penner et al. Dec 2002 A1
20020193679 Malave et al. Dec 2002 A1
20020193874 Crowley Dec 2002 A1
20020198470 Imran et al. Dec 2002 A1
20020198521 Maguire Dec 2002 A1
20020198604 Schulman et al. Dec 2002 A1
20030024534 Silvestri et al. Feb 2003 A1
20030040704 Dorros et al. Feb 2003 A1
20030060723 Joo et al. Mar 2003 A1
20030065250 Chiel et al. Apr 2003 A1
20030065358 Frecker et al. Apr 2003 A1
20030069475 Banik et al. Apr 2003 A1
20030069523 Williams et al. Apr 2003 A1
20030093031 Long et al. May 2003 A1
20030151524 Clark Aug 2003 A1
20030152823 Heller Aug 2003 A1
20030153866 Long et al. Aug 2003 A1
20030158584 Cates et al. Aug 2003 A1
20030163177 Eggers et al. Aug 2003 A1
20030167000 Mullick et al. Sep 2003 A1
20030191430 D'Andrea et al. Oct 2003 A1
20030214579 Iddan Nov 2003 A1
20030214580 Iddan Nov 2003 A1
20030220556 Porat et al. Nov 2003 A1
20040008853 Pelrine et al. Jan 2004 A1
20040018508 Friedman Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040064093 Hektner et al. Apr 2004 A1
20040073177 Hickle Apr 2004 A1
20040073190 Deem et al. Apr 2004 A1
20040092825 Madar et al. May 2004 A1
20040097819 Duarte May 2004 A1
20040098030 Makower et al. May 2004 A1
20040111019 Long Jun 2004 A1
20040133147 Woo Jul 2004 A1
20040138517 Osorio et al. Jul 2004 A1
20040147939 Rabkin et al. Jul 2004 A1
20040148034 Kagan et al. Jul 2004 A1
20040152988 Weirich Aug 2004 A1
20040162469 Imran Aug 2004 A1
20040162501 Imran Aug 2004 A1
20040176664 Iddan Sep 2004 A1
20040193010 Fujimori et al. Sep 2004 A1
20040199246 Chu et al. Oct 2004 A1
20040225325 Bonutti Nov 2004 A1
20040225326 Weiner et al. Nov 2004 A1
20040260391 Santini, Jr. et al. Dec 2004 A1
20040267240 Gross et al. Dec 2004 A1
20050004474 Iddan Jan 2005 A1
20050004553 Douk Jan 2005 A1
20050021023 Guglielmi et al. Jan 2005 A1
20050027236 Douk Feb 2005 A1
20050043583 Killmann et al. Feb 2005 A1
20050058701 Gross et al. Mar 2005 A1
20050062562 Ries Mar 2005 A1
20050065592 Holzer Mar 2005 A1
20050069925 Ford et al. Mar 2005 A1
20050079132 Wang et al. Apr 2005 A1
20050107870 Wang et al. May 2005 A1
20050113460 Glick May 2005 A1
20050121411 Cohen Jun 2005 A1
20050126916 Lockard et al. Jun 2005 A1
20050149170 Tassel et al. Jul 2005 A1
20050151524 Sae-Ueng et al. Jul 2005 A1
20050171418 Lin Aug 2005 A1
20050171434 Madden et al. Aug 2005 A1
20050177223 Palmaz Aug 2005 A1
20050182482 Wang et al. Aug 2005 A1
20050203613 Arney et al. Sep 2005 A1
20050215911 Alfano et al. Sep 2005 A1
20050216074 Sahatjian et al. Sep 2005 A1
20050221529 Bang et al. Oct 2005 A1
20050228259 Glukhovsky et al. Oct 2005 A1
20050234393 Wood Oct 2005 A1
20050234440 Wood Oct 2005 A1
20050238689 Carpenter et al. Oct 2005 A1
20050272806 Falotico et al. Dec 2005 A1
20050272974 Iddan Dec 2005 A1
20050277839 Alderman et al. Dec 2005 A1
20050278020 Wang et al. Dec 2005 A1
20060004395 Chiel et al. Jan 2006 A1
20060009810 Mann et al. Jan 2006 A1
20060015146 Girouard et al. Jan 2006 A1
20060037617 Walke et al. Feb 2006 A1
20060042631 Martin et al. Mar 2006 A1
20060074479 Bailey et al. Apr 2006 A1
20060119304 Farritor et al. Jun 2006 A1
20060152309 Mintchev et al. Jul 2006 A1
20060167339 Gilad et al. Jul 2006 A1
20060169294 Kaler et al. Aug 2006 A1
20060235275 Rabinovitz et al. Oct 2006 A1
20060252987 Hasegawa et al. Nov 2006 A1
20070010868 Ferren et al. Jan 2007 A1
20070066929 Ferren et al. Mar 2007 A1
20070088334 Hillis et al. Apr 2007 A1
20070156211 Ferren et al. Jul 2007 A1
20070225634 Ferren et al. Sep 2007 A1
20080063703 Gross et al. Mar 2008 A1
20080066929 Costa et al. Mar 2008 A1
20080103440 Ferren et al. May 2008 A1
20080121054 Goldenberg et al. May 2008 A1
20080241847 Hoon et al. Oct 2008 A1
20080243056 Hillis et al. Oct 2008 A1
20080266106 Lim et al. Oct 2008 A1
20090062646 Creighton, IV et al. Mar 2009 A1
20090069821 Farritor et al. Mar 2009 A1
20090082652 Koh et al. Mar 2009 A1
20090182388 Von Arx et al. Jul 2009 A1
Foreign Referenced Citations (22)
Number Date Country
99810271.7 Oct 2001 CN
1 245 201 Oct 2002 EP
1 618 831 Jan 2006 EP
2 163 206 Mar 2010 EP
2001-506871 Mar 1998 JP
2002-153569 May 2002 JP
2005-74229 Mar 2005 JP
WO 9639999 Dec 1996 WO
WO 9809582 Mar 1998 WO
WO 9814243 Apr 1998 WO
WO 9920335 Apr 1999 WO
WO 9944665 Sep 1999 WO
WO 0069515 Nov 2000 WO
WO 0108548 Feb 2001 WO
WO 0124731 Apr 2001 WO
WO 03072157 Sep 2003 WO
WO 03090618 Nov 2003 WO
WO 03106966 Dec 2003 WO
WO 2004028335 Apr 2004 WO
WO 2004058041 Jul 2004 WO
WO 2004086958 Oct 2004 WO
WO 2005082248 Sep 2005 WO
Related Publications (1)
Number Date Country
20060069425 A1 Mar 2006 US